Canada Alzheimers Therapeutics Market Size & Outlook
Canada alzheimers therapeutics market, 2018-2030 (US$M)
Related Markets
Canada alzheimers therapeutics market highlights
- The Canada alzheimers therapeutics market generated a revenue of USD 136.7 million in 2022 and is expected to reach USD 381.9 million by 2030.
- The Canada market is expected to grow at a CAGR of 13.7% from 2023 to 2030.
- In terms of segment, cholinesterase inhibitors was the largest revenue generating drug class in 2022.
- Monoclonal Antibodies is the most lucrative drug class segment registering the fastest growth during the forecast period.
Alzheimers therapeutics market data book summary
| Market revenue in 2022 | USD 136.7 million |
| Market revenue in 2030 | USD 381.9 million |
| Growth rate | 13.7% (CAGR from 2022 to 2030) |
| Largest segment | Cholinesterase inhibitors |
| Fastest growing segment | Monoclonal Antibodies |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cholinesterase inhibitors, NMDA Receptor Antagonist, Combination Drugs, Monoclonal Antibodies |
| Key market players worldwide | Eisai Co Ltd, Novartis AG ADR, AbbVie Inc, H. Lundbeck AS Class A, Biogen Inc, Roche Holding AG ADR, Daiichi Sankyo Co Ltd, Johnson & Johnson, AC Immune SA |
Other key industry trends
- In terms of revenue, Canada accounted for 3.2% of the global alzheimers therapeutics market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. alzheimers therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 6,441.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Alzheimers Therapeutics Market Scope
Alzheimers Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada alzheimers therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to alzheimers therapeutics market will help companies and investors design strategic landscapes.
Cholinesterase inhibitors was the largest segment with a revenue share of 51.79% in 2022. Horizon Databook has segmented the Canada alzheimers therapeutics market based on cholinesterase inhibitors, nmda receptor antagonist, combination drugs, monoclonal antibodies covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing incidence of Alzheimer's dementia in the geriatric population and growing government initiatives to create awareness about AD are factors expected to drive market growth. According to the Alzheimer Society of Canada, there are more than 500,000 people in Canada living with dementia, and the number is estimated to reach 912,000 by the year 2030.
The Public Health Agency of Canada (PHAC) supports the Centre for Aging and Brain Health Innovation in developing, testing, and scaling up products & services to improve brain health with focus on dementia. The government is supporting R&D organizations in creating innovative and effective treatment for AD.
Reasons to subscribe to Canada alzheimers therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Canada alzheimers therapeutics market databook
-
Our clientele includes a mix of alzheimers therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada alzheimers therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Canada alzheimers therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Canada alzheimers therapeutics market size, by drug class, 2018-2030 (US$M)
Canada Alzheimers Therapeutics Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
